Matching articles for "DVT"
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • October 7, 2019; (Issue 1582)
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate...
Patients who receive pretravel advice can reduce their
risk for many travel-related conditions. Vaccines recommended
for travelers are reviewed in a separate issue.
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
The Medical Letter on Drugs and Therapeutics • December 3, 2018; (Issue 1561)
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular...
The FDA has approved a new 2.5-mg formulation of
the direct factor Xa inhibitor rivaroxaban (Xarelto –
Janssen) for use in combination with low-dose aspirin
to reduce the risk of major cardiovascular events in
patients with chronic coronary artery disease (CAD)
or peripheral artery disease (PAD). Rivaroxaban is
the first direct oral anticoagulant to be approved for
this indication. It was approved earlier for prevention
and treatment of deep vein thrombosis (DVT) or
pulmonary embolism (PE) and for prevention of stroke
and systemic embolism in patients with nonvalvular
atrial fibrillation.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • April 13, 2015; (Issue 1466)
Patients planning to travel to other countries often
ask for information about prevention of diarrhea,
malaria, and other travel-related conditions. Vaccines
recommended for travelers based on their...
Patients planning to travel to other countries often
ask for information about prevention of diarrhea,
malaria, and other travel-related conditions. Vaccines
recommended for travelers based on their destination,
length of stay, and planned activities were reviewed in
a previous issue.
New Oral Anticoagulants for Acute Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • January 6, 2014; (Issue 1433)
Anticoagulants are the drugs of choice for treatment
of deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively referred to as venous
thromboembolism...
Anticoagulants are the drugs of choice for treatment
of deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively referred to as venous
thromboembolism (VTE).
Rivaroxaban (Xarelto) for Acute Coronary Syndrome
The Medical Letter on Drugs and Therapeutics • December 12, 2011; (Issue 1379)
The standard antithrombotic therapy for treatment of
patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy with aspirin and clopidogrel (Plavix)
or another thienopyridine, plus a...
The standard antithrombotic therapy for treatment of
patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy with aspirin and clopidogrel (Plavix)
or another thienopyridine, plus a parenteral anticoagulant
while the patient is hospitalized, followed by antiplatelet
therapy alone after discharge. The addition of the oral
anticoagulant warfarin (Coumadin, and others) to dual
antiplatelet therapy is generally not recommended for this
indication because of fluctuations in its anticoagulant
effect and the risk of bleeding. A recently published trial
found that addition of a low dose of the oral anticoagulant
rivaroxaban (Xarelto) to antiplatelet therapy after discharge
reduced the risk of major cardiovascular events
without increasing the incidence of fatal bleeding.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • October 1, 2011; (Issue 110)
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but...
Arterial thrombi are composed mainly of platelet
aggregates held together by small amounts of fibrin.
Antiplatelet drugs are the drugs of choice for prevention
and treatment of arterial thrombosis, but anticoagulants
are also effective, and their effects can add to those of
antiplatelet drugs. Venous thrombi are composed
mainly of fibrin and trapped red blood cells, with relatively
few platelets. Anticoagulants are the agents of
choice for prevention and treatment of venous thromboembolism
and for prevention of cardioembolic
events in patients with atrial fibrillation.
Rivaroxaban (Xarelto) - A New Oral Anticoagulant
The Medical Letter on Drugs and Therapeutics • August 22, 2011; (Issue 1371)
The FDA has approved rivaroxaban (Xarelto –
Janssen), an oral direct factor Xa inhibitor, for prevention
of deep vein thrombosis (DVT) in patients undergoing
knee or hip replacement...
The FDA has approved rivaroxaban (Xarelto –
Janssen), an oral direct factor Xa inhibitor, for prevention
of deep vein thrombosis (DVT) in patients undergoing
knee or hip replacement surgery.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • November 1, 2009; (Issue 87)
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases...
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • May 1, 2006; (Issue 45)
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers...
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel.
Advice for Travelers
The Medical Letter on Drugs and Therapeutics • May 1, 2004; (Issue 21)
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for...
Patients planning to travel to other countries often ask physicians for advice about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control (CDC) at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel. Recommendations for the treatment of parasitic diseases are available in the public reading room of The Medical Letter's web site.
Fondaparinux (Arixtra), A New Anticoagulant
The Medical Letter on Drugs and Therapeutics • May 13, 2002; (Issue 1130)
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip...
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip replacement.
Tinzaparin, A Low Molecular Weight Heparin For Treatment of Deep Vein Thrombosis
The Medical Letter on Drugs and Therapeutics • February 19, 2001; (Issue 1098)
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein...
Tinzaparin sodium, a low molecular weight heparin, has been approved by the FDA for treatment of acute deep vein thrombosis.